Icosabutate not checked
NorthSea Therapeutics B.V. · NST-4016
FollowEvery change as it happens, and a Monday email
Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Non Alcoholic Steatohepatitis (NASH)
- Main trialPhase 2
- “A Phase 2b study to evaluate the efficacy of different doses of NST-4016 on the resolution of NASH without worsening of fibrosis”In the company’s words, NCT04052516 on ClinicalTrials.gov
- Other names
- NST-4016
Other drugs for Non Alcoholic Steatohepatitis (NASH)
- ResmetiromMadrigal Pharmaceuticals · Phase 3
- ALN-CIDEBRegeneron · Alnylam · Phase 3
- Efimosfermin AlfaGSK · Phase 3
- PegozaferminHoffmann-La Roche · 89bio, Inc. · Phase 3
- DR10624Zhejiang Doer Biologics Co., Ltd. · Phase 3
- SemaglutideNovo Nordisk · Phase 3
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Completed | 20 Feb 2022 | A Phase 2b Study of Icosabutate in Fatty Liver Disease |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026